孢子菌病:最近基于药物的治疗和管理的综合综述。

IF 2.4 Q2 DERMATOLOGY
Current Dermatology Reports Pub Date : 2022-01-01 Epub Date: 2022-03-17 DOI:10.1007/s13671-022-00358-5
Bunty Sharma, Anil Kumar Sharma, Ujjawal Sharma
{"title":"孢子菌病:最近基于药物的治疗和管理的综合综述。","authors":"Bunty Sharma,&nbsp;Anil Kumar Sharma,&nbsp;Ujjawal Sharma","doi":"10.1007/s13671-022-00358-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Over a period of time, sporotrichosis has arisen as one of the leading fungal infections not only in animals but humans also. Several possible reasons that contribute to its emergence include change in epidemiology and distribution, evolutionary changes in taxonomy, and several outbreaks. World Health Organization has identified sporotrichosis as one of the major neglected tropical diseases (NTD) for 2021-2030 under the category of fungal NTDs. Several factors are contributing to increases in morbidity due to sporotrichosis such as delayed diagnosis and unavailability of appropriate antifungal therapy, which lead to redundant and inappropriate treatment with associate costs and adverse effects.</p><p><strong>Recent findings: </strong>The potassium iodide is the first line of treatment for cutaneous forms while amphotericin B is used for the most severe cases of the disease. The limited medication arsenal, side effects, failure of therapy, and the advent of drug-resistant isolates emphasize the need for the development of new therapeutic options. Several studies are focusing on the development of the new drugs which either used alone or in combination with already available treatment. Along with this, several new antigens have been identified as possible targets for its vaccine development.</p><p><strong>Summary: </strong>The early diagnosis is required for selecting the best possible treatment strategy. The researchers should focus on developing new diagnostic methods and treatment options as well as vaccine development for the better management of sporotrichosis. In the long run, patient education for preventative features to reduce risk and counselling for prolonged therapy will be beneficial.</p>","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927753/pdf/","citationCount":"8","resultStr":"{\"title\":\"Sporotrichosis: a Comprehensive Review on Recent Drug-Based Therapeutics and Management.\",\"authors\":\"Bunty Sharma,&nbsp;Anil Kumar Sharma,&nbsp;Ujjawal Sharma\",\"doi\":\"10.1007/s13671-022-00358-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose of review: </strong>Over a period of time, sporotrichosis has arisen as one of the leading fungal infections not only in animals but humans also. Several possible reasons that contribute to its emergence include change in epidemiology and distribution, evolutionary changes in taxonomy, and several outbreaks. World Health Organization has identified sporotrichosis as one of the major neglected tropical diseases (NTD) for 2021-2030 under the category of fungal NTDs. Several factors are contributing to increases in morbidity due to sporotrichosis such as delayed diagnosis and unavailability of appropriate antifungal therapy, which lead to redundant and inappropriate treatment with associate costs and adverse effects.</p><p><strong>Recent findings: </strong>The potassium iodide is the first line of treatment for cutaneous forms while amphotericin B is used for the most severe cases of the disease. The limited medication arsenal, side effects, failure of therapy, and the advent of drug-resistant isolates emphasize the need for the development of new therapeutic options. Several studies are focusing on the development of the new drugs which either used alone or in combination with already available treatment. Along with this, several new antigens have been identified as possible targets for its vaccine development.</p><p><strong>Summary: </strong>The early diagnosis is required for selecting the best possible treatment strategy. The researchers should focus on developing new diagnostic methods and treatment options as well as vaccine development for the better management of sporotrichosis. In the long run, patient education for preventative features to reduce risk and counselling for prolonged therapy will be beneficial.</p>\",\"PeriodicalId\":10838,\"journal\":{\"name\":\"Current Dermatology Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927753/pdf/\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13671-022-00358-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/3/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13671-022-00358-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 8

摘要

综述目的:近年来,孢子虫病已成为动物和人类的主要真菌感染之一。导致其出现的几个可能原因包括流行病学和分布的变化、分类学的进化变化以及几次暴发。世界卫生组织已将孢子虫病确定为2021-2030年被忽视的主要热带病(NTD)之一,属于真菌性被忽视热带病类别。有几个因素导致孢子菌病的发病率增加,如诊断延误和无法获得适当的抗真菌治疗,这导致了重复和不适当的治疗,并伴有相关的费用和不良反应。最近的发现:碘化钾是治疗皮肤形式的第一线,而两性霉素B用于最严重的病例。有限的药物库、副作用、治疗失败以及耐药分离株的出现强调了开发新的治疗选择的必要性。一些研究的重点是开发新的药物,这些药物可以单独使用,也可以与现有的治疗方法结合使用。与此同时,已经确定了几种新的抗原作为其疫苗开发的可能目标。总结:早期诊断是选择最佳治疗策略的必要条件。研究人员应该把重点放在开发新的诊断方法和治疗方案以及疫苗开发上,以便更好地管理孢子虫病。从长远来看,对患者进行预防教育以降低风险,并为长期治疗提供咨询将是有益的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Sporotrichosis: a Comprehensive Review on Recent Drug-Based Therapeutics and Management.

Sporotrichosis: a Comprehensive Review on Recent Drug-Based Therapeutics and Management.

Purpose of review: Over a period of time, sporotrichosis has arisen as one of the leading fungal infections not only in animals but humans also. Several possible reasons that contribute to its emergence include change in epidemiology and distribution, evolutionary changes in taxonomy, and several outbreaks. World Health Organization has identified sporotrichosis as one of the major neglected tropical diseases (NTD) for 2021-2030 under the category of fungal NTDs. Several factors are contributing to increases in morbidity due to sporotrichosis such as delayed diagnosis and unavailability of appropriate antifungal therapy, which lead to redundant and inappropriate treatment with associate costs and adverse effects.

Recent findings: The potassium iodide is the first line of treatment for cutaneous forms while amphotericin B is used for the most severe cases of the disease. The limited medication arsenal, side effects, failure of therapy, and the advent of drug-resistant isolates emphasize the need for the development of new therapeutic options. Several studies are focusing on the development of the new drugs which either used alone or in combination with already available treatment. Along with this, several new antigens have been identified as possible targets for its vaccine development.

Summary: The early diagnosis is required for selecting the best possible treatment strategy. The researchers should focus on developing new diagnostic methods and treatment options as well as vaccine development for the better management of sporotrichosis. In the long run, patient education for preventative features to reduce risk and counselling for prolonged therapy will be beneficial.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.30
自引率
6.20%
发文量
28
期刊介绍: This journal intends to review the most significant recent developments in the field of dermatology. By providing clear, insightful, balanced contributions by expert international authors, the journal aims to serve all those involved in the diagnosis, treatment, management, and prevention of dermatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field, such as epidemiology, surgery, pharmacology, clinical trial design, and pediatrics. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known figures in the field, and an Editorial Board of more than 20 internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信